Lamellar Ichthyosis Treatment Market

Lamellar Ichthyosis Treatment Market Overview

The global Lamellar Ichthyosis Treatment Market is anticipated to achieve a high CAGR during the forecast period spanning from 2023 to 2030.

Understanding Lamellar Ichthyosis
Lamellar Ichthyosis, also known as collodion baby or congenital lamellar ichthyosis, is a rare genetic skin disorder present at birth. It falls under the category of autosomal recessive congenital ichthyoses (ARCI) and is characterized by cutaneous redness and extensive scaling. Caused by harmful genetic mutations, the most common gene related to this condition is TGM1, with other genes including NIPAL4, ALOX12B, and CYP4F22.

Though not life-threatening, lamellar ichthyosis causes severe skin disfigurement, and as of now, there is no proven cure. Treatment primarily aims to manage symptoms, focusing on preventing excessive transepidermal water loss and subsequent infections. Topical treatments, including moisturizing creams, emollients, keratolytic creams, antibiotics, and retinoids, are commonly used.

Market Dynamics
Increasing Adoption of Topical Medications
The market is being driven by the growing adoption of topical medications, coupled with the development of novel and advanced topical treatments. Topical medicines, including moisturizing creams, play a crucial role in managing visible symptoms like thick scales and dry skin in lamellar ichthyosis. Pharmaceutical companies are actively involved in developing innovative topical agents.

Example: Timber Pharmaceuticals received Fast Track designation from the FDA for TMB-001, a topical isotretinoin, for the treatment of lamellar ichthyosis.
Prevalence and Clinical Trials
The increasing prevalence of lamellar ichthyosis is contributing to the demand for topical agents. Research institutions and pharmaceutical companies are conducting clinical trials to develop better treatment options. According to the National Institute of Health (NIH), lamellar ichthyosis is a rare disorder with a prevalence of less than 1 case per 300,000 individuals.

Advantages of Topical Medications
Topical medications, with their localized effects, offer advantages over systemic medications. They reduce the risk of systemic side effects and are more convenient for long-term use. Their ease of application enhances treatment adherence, increasing their adoption.

Request for Free Sample: https://www.datamintelligence.com/download-sample/lamellar-ichthyosis-treatment-market

Market Restraints
Complications and adverse effects associated with topical creams, high treatment costs, the availability of alternative treatments, and the lack of a definitive cure for lamellar ichthyosis are expected to restrain market growth.

Lamellar Ichthyosis Treatment Market Segment Analysis
The global lamellar ichthyosis treatment market is segmented based on treatment type, route of administration, distribution channel, and region.

Moisturizing Creams Segment: Accounting for approximately 53.2% of the market share, moisturizing creams are expected to dominate the market. These creams are considered the first-line treatment for managing lamellar ichthyosis symptoms, providing symptomatic relief and improving skin texture.
Geographical Shares
North America Leading the Market
North America, particularly the United States, is expected to hold the largest market share. Advanced healthcare infrastructure, ongoing research activities, and the prevalence of lamellar ichthyosis contribute to this dominance. The United States, with a prevalence of 1 in 100,000 individuals, hosts numerous research institutions and pharmaceutical companies actively involved in developing treatments.

Market Companies
Major global players in the lamellar ichthyosis treatment market include LGM Pharma, Mylan Inc., Sebapharma GmbH & Co. KG, Timber Pharmaceuticals LLC, Galderma SA, Beiersdorf AG, DFB Technology, Ltd., Unilever PLC, LANOLIPS PTY LTD, and Lanolin Beauty International.

COVID-19 Impact Analysis
The COVID-19 pandemic significantly affected the global lamellar ichthyosis treatment market. Clinical trials and research activities were disrupted due to the redirected focus on COVID-19. Challenges in conducting trials, enrolling participants, and ensuring continuity delayed the development of new treatments. The pandemic also disrupted the global supply chain of lamellar ichthyosis treatment medicines.

Media Contact
Company Name: DataM Intelligence
Email: info@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com/

About DataM Intelligence
DataM Intelligence 4Market Research is a Market Research firm that provides end-to-end business solutions to organizations from Research to Consulting. We at DataM Intelligence leverage our top trademark trends, insights, and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of Syndicate Reports & and; Customized Reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries, catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.